+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07058883

Randomized Clinical Trial Evaluating Juline Injectable Device for Moderate to Severe Facial Acne Scars Treatment

Led by Nordberg Medical AB · Updated on 2026-10-02

55

Participants Needed

2

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating Juline, an injectable medical device made of polylactic acid, for treating moderate to severe atrophic facial acne scars. This randomized, double-blind, placebo-controlled trial involves 55 adult participants who will be assigned to receive either Juline or a saline placebo. The study is conducted in multiple dermatology clinics in Poland and has received ethical approval. Participants will receive three intradermal injection sessions of either Juline or placebo at Day 0, Day 30, and Day 60, targeting areas affected by acne scars. Following the treatment phase, participants will be observed for 12 months to monitor changes in scar severity and skin quality. The study adheres to strict quality and regulatory standards. During the trial, participants will undergo clinical assessments, imaging evaluations including Canfield VISIA and high-frequency ultrasound, and skin elasticity and hydration measurements at multiple timepoints. Researchers will measure improvements in acne scars at 6 and 12 months, along with patient satisfaction and global aesthetic improvement. Safety monitoring includes the collection of adverse events and tolerability assessments throughout the 12-month follow-up period.

CONDITIONS

Brief Title

Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars

Research Team

P

Paweł Kubik, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here